Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jun
18
Today In Oncology
New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer
Preclinical Research Shows Interferon May Attenuate Neutrophil Response to Cancer Immunotherapy
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia
Relapsed or Refractory Multiple Myeloma Talquetamab Daratumumab
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo